Based on the technology, the market is divided into Jet-based needle-free injectors, spring-based needle-free injectors, laser-based needle-free injectors and vibration-based needle-free injectors. The jet-based needle-free injector is expected to account for the largest market share in 2016, due to their advantages over the other injector systems.

Expected Revenue Growth :

The global needle-free injection system market, in terms of value, is projected to reach USD 20.17 Billion by 2021 from USD 9.81 Billion in 2016, at a CAGR of 15.5% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=165815861

What This Report Will Provide?

The needle-free injection system market is fragmented with several global as well as local players. Players in this market offer several detectors across different subsegments of this market. The report segments the market based on product, technology, type, site of delivery, applications, end user and regions. Based on the technology, the market is divided into Jet-based needle-free injectors, spring-based needle-free injectors, laser-based needle-free injectors and vibration-based needle-free injectors.

Target Audience:

• Needle-free Injection Manufacturers
• Needle-free Injection Instrument Manufacturers and Suppliers
• Research and Development Companies
• Medical Research Laboratories
• Academics Medical Centers and Universities
• Research and Consulting Firms

Key developments:

• In 2020, Lonza (Switzerland) collaborated with IsoPlexis (US) to develop the next generation of precision cell therapy manufacturing.
• In 2020, Biopharma business from General Electric Company’s Life Sciences division (US) Danaher acquired the Biopharma business from General Electric Company’s Life Sciences division. The acquisition led to a new business named Cytiva, a standalone operating company within Danaher’s Life Sciences segment.
• In 2019, Thermo Fisher Scientific invested ~USD 24 million in its Inchinnan (Scotland) site to expand its global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell culture media.
• In 2018, FUJIFILM Irvine Scientific (US) launched PRIME-XV NK Cell CDM, chemically-defined (CDM), animal component-free (ACF) medium for the ex vivo expansion of NK cells. The medium offers natural killer (NK) cell expansion while preserving NK cell potency and functionality.
• In 2017, STEMCELL Technologies signed an exclusive license with Propagenix to commercialize EpiX, an innovation empowering epithelial cell biology and cell therapy.

Request Sample Report:  https://www.marketsandmarkets.com/requestsampleNew.asp?id=165815861  

Major Growth Boosters:

Growth in this market is mainly driven by growing prevalence of chronic disease, increasing incidence of communicable disease due to needle stick injuries, rising demand for biosimilars and vaccination, advantages of drug delivery technology, increasing demand for self-injection devices. On the other hand, high development cost of needle-free injection systems over the conventional needle injection may hinder the growth of this market during the forecast period.

Regional Growth Analysis:

North America is expected to dominate the market in 2016, with the U.S. accounting for a major share. However, Europe is expected to grow at the highest CAGR during the forecast period. The high growth in this market is attributed to the rising demand for biologics, growing prevalence of chronic diseases, technological advancements, mergers and acquisitions by major companies in the market, favorable reimbursement policies, increasing healthcare expenditure and regulatory approvals of new injection system are key factors driving the market growth in Europe.